HOME › Top Market Reports › Global Clinical Trials Market (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)

Global Clinical Trials Market (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)

By: marketsandmarkets.com
Publishing Date: September 2011
Report Code: PH 1622

Please click here to get the updated version of e-Clinical Trials Solutions/Suite/Technologies Market – (CTMS, CDMS, EDC, IVRS, ePRO & IRB Systems) Global Trends, Opportunities & Forecasts (2012 – 2017)

Clinical trials market now witnesses a paradigm shift. Naïve heterogeneous patient populations in the developing nations are opening up new avenues for the clinical trials market. Developing countries also offer faster means; which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the pharma-biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted.

Today, emerging countries account for the largest share of the phase II/III (prime stages) clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic, and cardiovascular diseases. Support from the respective government bodies is one of the major factors affecting the clinical trials market. Clinical trials sponsored by the industry have a much higher share in the market as compared to government organizations.

North America includes the U.S. and Canada; together both the countries have reported to have the largest number of clinical trials conducted globally. In the European region, Germany heads the largest number of clinical trials, the country was reported to have conducted 734 trials for 2010 in Western Europe while Poland accounted for the largest number of clinical trials in Eastern Europe with total number of 263 clinical trials for 2010.

Asia is one of the fastest growing markets for global clinical trials. The countries taking lead in this market are India, China, South Korea, and Singapore. The major reasons for this market to have high potential are its huge and diverse population with diseases that are present in both - the developed and under developed countries. Hence, different types of trials can be conducted in one region. Due to large population, it helps in faster recruitment of the patients, and retention of the participants in the trials on the higher side; thereby helping the companies to conduct the trials on the timely basis.

The financial targets and global competition are forcing the pharmaceutical players to look out for various options to introduce novel therapies in the market. At the same time, emerging shortage of clinical resources such as lack of naïve disease population, well trained labor, and sound medical infrastructure are delaying the process to initiate trials. Hence, all these companies are considering Latin America as an alternative option for conducting clinical trials.

The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare, PPD, Parexel, Kendle, and Quintles.

The global clinical trials conducted in 2008 were reported to be 10,326 and were highest from 2007 to 2010. Oncology trials were the most widely conducted clinical trials accounting for 28.47% of all the trials conducted for the year 2008. Asia reported to a steady growth as compared to the other regions; which showed decline in the total number of clinical trials in the year 2010.

Scope of the report

Global clinical trials market research report categorizes by phases, by the study design, by the disease indications and with analysis of the geographic trends of conducting the clinical trials.

Clinical trials market by phases:

Phase I
Phase II
Phase III

Clinical trials market by study design

Interventional trials
Observational trials
Expanded Access trials.

Clinical trials market by indications

Autoimmune
Blood disorders
Cancer
Circulatory
CNS
Congenital
CVS
Dermatology
Ear
Gastrointestinal
Genitourinary
Infections
Mental disorders
Metabolic
Musculoskeletal
Nose
Ophthalmology
Others

Clinical trials on basis of geography:

North America
South America
Asia
Europe

Each section of the report provides market tables for covering the number of clinical trials conducted between 2007 and 2010.

In addition, the report also provides 19 company profiles of the CROs covering the services and geographic presence.

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY

2 EXECUTIVE SUMMARY
2.1 OVERVIEW OF THE MARKET
2.2 KEY FINDINGS

3 MARKET OVERVIEW
3.1 MARKET DEFINITION
3.2 DRIVERS
      3.2.1 GLOBALIZING DRUG DEVELOPMENT ACTIVITIES
      3.2.2 RISE IN R&D INVESTMENTS EXPECTED TO BOOST THE CLINICAL TRIALS MARKET
      3.2.3 HIGH DISEASE PREVALENCE IN EMERGING COUNTRIES
3.3 RESTRAINTS
      3.3.1 LONGER APPROVAL TIME FOR CLINICAL TRIALS – A CAUSE OF CONCERN FOR MAJOR PHARMACEUTICAL-BIOTECHNOLOGY PLAYERS
3.4 BURNING ISSUES
      3.4.1 OUT SKIRTING BOUNDARIES OF MEDICAL ETHICS
3.5 WINNING IMPERATIVES
      3.5.1 LEVERAGING ONLINE RESOURCES TO INCREASE PATIENT RECRUITMENT RATES IN CLINICAL TRIALS
3.6 COUNTRY COMPARISON
3.7 INDUSTRY TRENDS
      3.7.1 ENGAGING CLINICAL TRIALS IN EMERGING COUNTRIES & LOW COST CRO’S PROVE TO BE COMPELLING OPTIONS IN TIMES OF DRUG PATENT EXPIRY
      3.7.2 CROS LEVERAGING THE BENEFITS OF EMERGING MARKETS
      3.7.3 CHANGING CRO BUSINESS MODELS
            3.7.3.1 Full service model
            3.7.3.2 Hourly billing model
            3.7.3.3 Full time equivalent model (FTE)
            3.7.3.4 Fixed price model
      3.7.4 PREVALENCE OF PREFERRED PROVIDER RELATIONSHIPS
      3.7.5 SHIFT TOWARDS PATIENT CENTRIC CLINICAL TRIALS DUE TO TECHNICAL ADVANCES
3.8 GLOBAL CLINICAL TRIALS MARKET
      3.8.1 OFFSHORING & OUTSOURCING

4 CLINICAL TRIALS MARKET, BY TYPES
4.1 INTRODUCTION
      4.1.1 CLINICAL TRIALS MARKET, BY STUDY PHASES
            4.1.1.1 Preclinical studies
            4.1.1.2 Phase I trials
            4.1.1.3 Phase II trials
            4.1.1.4 Phase I/II
            4.1.1.5 Phase II/III
            4.1.1.6 Phase III trials
      4.1.2 CLINICAL TRIALS MARKET, BY STUDY DESIGNS
            4.1.2.1 Observational studies
            4.1.2.2 Interventional studies
            4.1.2.3 Expanded Access Trials
      4.1.3 CLINICAL TRIALS MARKET, BY INDICATIONS

5 GEOGRAPHIC ANALYSIS
5.1 NORTH AMERICA
      5.1.1 U.S.
            5.1.1.1 Regulatory environment
            5.1.1.2 Clinical trials registry
            5.1.1.3 Government support
      5.1.2 CANADA
            5.1.2.1 Regulatory environment
            5.1.2.2 Clinical trials registry
            5.1.2.3 Government support
5.2 EUROPE
      5.2.1 UK
            5.2.1.1 Regulatory environment
            5.2.1.2 Clinical trials registry
            5.2.1.3 Government support
      5.2.2 GERMANY
            5.2.2.1 Regulatory environment
            5.2.2.2 Clinical trials registry
            5.2.2.3 Government support
      5.2.3 ITALY
            5.2.3.1 Regulatory environment
            5.2.3.2 Clinical trials registry
            5.2.3.3 Government support
      5.2.4 FRANCE
            5.2.4.1 Regulatory environment
            5.2.4.2 Clinical trials registry
            5.2.4.3 Support rendered by the government
      5.2.5 SPAIN
            5.2.5.1 Regulatory environment
            5.2.5.2 Clinical trials registry
            5.2.5.3 Government support
      5.2.6 POLAND
            5.2.6.1 Regulatory environment
            5.2.6.2 Clinical trials registry
            5.2.6.3 Support rendered by the Government
      5.2.7 RUSSIA
            5.2.7.1 Regulatory environment
            5.2.7.2 Clinical trials registry
            5.2.7.3 Support rendered by the Government
      5.2.8 TURKEY
            5.2.8.1 Regulatory environment
            5.2.8.2 Clinical trials registry
            5.2.8.3 Government support
      5.2.9 UKRAINE
            5.2.9.1 Regulatory environment
            5.2.9.2 Clinical trials registry
            5.2.9.3 Support rendered by the Government
5.3 ASIA
      5.3.1 CHINA
            5.3.1.1 Clinical trials registry
            5.3.1.2 Government support
      5.3.2 INDIA
            5.3.2.1 Regulatory environment
            5.3.2.2 Clinical trials registry
            5.3.2.3 Government support
      5.3.3 SOUTH KOREA
            5.3.3.1 Regulatory environment
            5.3.3.2 Clinical trials registry
            5.3.3.3 Government support
5.4 LATIN AMERICA
      5.4.1 BRAZIL
            5.4.1.1 Regulatory environment
            5.4.1.2 Clinical trials registry
            5.4.1.3 Government support
      5.4.2 MEXICO
            5.4.2.1 Regulatory environment
            5.4.2.2 Clinical trials registry
            5.4.2.3 Government support
      5.4.3 ARGENTINA
            5.4.3.1 Regulatory environment
            5.4.3.2 Clinical trials registry
            5.4.3.3 Government support

6 COMPETITIVE LANDSCAPE
6.1 INTRODUCTION

7 COMPANY PROFILES
7.1 AAIPHARMA SERVICES CORP.
      7.1.1 OVERVIEW
      7.1.2 FINANCIALS
      7.1.3 PRODUCTS & SERVICES
      7.1.4 STRATEGY
      7.1.5 DEVELOPMENTS
7.2 ACCELL CLINICAL RESEARCH LLC
      7.2.1 OVERVIEW
      7.2.2 FINANCIALS
      7.2.3 PRODUCTS & SERVICES
      7.2.4 STRATEGY
      7.2.5 DEVELOPMENTS
7.3 APTIV SOLUTIONS
      7.3.1 OVERVIEW
      7.3.2 FINANCIALS
      7.3.3 PRODUCTS & SERVICES
      7.3.4 STRATEGY
      7.3.5 DEVELOPMENTS
7.4 CHILTERN INTERNATIONAL LIMITED
      7.4.1 OVERVIEW
      7.4.2 FINANCIALS
      7.4.3 PRODUCTS & SERVICES
      7.4.4 STRATEGY
      7.4.5 DEVELOPMENTS
7.5 CONGENIX
      7.5.1 OVERVIEW
      7.5.2 FINANCIALS
      7.5.3 PRODUCTS & SERVICES
      7.5.4 STRATEGY
      7.5.5 DEVELOPMENTS
7.6 COVANCE INC.
      7.6.1 OVERVIEW
      7.6.2 FINANCIALS
      7.6.3 PRODUCTS & SERVICES
      7.6.4 STRATEGY
      7.6.5 DEVELOPMENTS
7.7 ECRON ACUNOVA LTD
      7.7.1 OVERVIEW
      7.7.2 FINANCIALS
      7.7.3 PRODUCTS & SERVICES
      7.7.4 STRATEGY
      7.7.5 DEVELOPMENTS
7.8 EUROTRIALS
      7.8.1 OVERVIEW
      7.8.2 FINANCIALS
      7.8.3 PRODUCTS & SERVICES
      7.8.4 DEVELOPMENTS
7.9 ICON PLC
      7.9.1 OVERVIEW
      7.9.2 FINANCIALS
      7.9.3 PRODUCTS & SERVICES
      7.9.4 STRATEGY
      7.9.5 DEVELOPMENTS
7.10 INC RESEARCH LLC
      7.10.1 OVERVIEW
      7.10.2 FINANCIALS
      7.10.3 PRODUCTS & SERVICES
      7.10.4 STRATEGY
      7.10.5 DEVELOPMENTS
7.11 MEDPACE INC
      7.11.1 OVERVIEW
      7.11.2 FINANCIALS
      7.11.3 PRODUCTS & SERVICES
      7.11.4 STRATEGY
      7.11.5 DEVELOPMENTS
7.12 PAREXEL INTERNATIONAL CORP
      7.12.1 OVERVIEW
      7.12.2 FINANCIALS
      7.12.3 PRODUCTS & SERVICES
      7.12.4 STRATEGY
      7.12.5 DEVELOPMENTS
7.13 PHARMANET DEVELOPMENT GROUP
      7.13.1 OVERVIEW
      7.13.2 FINANCIALS
      7.13.3 PRODUCTS & SERVICES
      7.13.4 STRATEGY
      7.13.5 DEVELOPMENTS
7.14 PHARMACEUTICAL PRODUCT DEVELOPMENT INC
      7.14.1 OVERVIEW
      7.14.2 FINANCIALS
      7.14.3 PRODUCTS & SERVICES
      7.14.4 STRATEGY
      7.14.5 DEVELOPMENTS
7.15 PRA INTERNATIONAL
      7.15.1 OVERVIEW
      7.15.2 FINANCIALS
      7.15.3 PRODUCTS & SERVICES
      7.15.4 STRATEGY
      7.15.5 DEVELOPMENTS
7.16 QUINTILES TRANSNATIONAL CORP
      7.16.1 OVERVIEW
      7.16.2 FINANCIALS
      7.16.3 PRODUCTS & SERVICES
      7.16.4 STRATEGY
      7.16.5 DEVELOPMENTS
7.17 SIRO CLINPHARM PVT. LTD
      7.17.1 OVERVIEW
      7.17.2 FINANCIALS
      7.17.3 PRODUCTS & SERVICES
      7.17.4 STRATEGY
      7.17.5 DEVELOPMENTS
7.18 TCG LIFESCIENCES LTD
      7.18.1 OVERVIEW
      7.18.2 FINANCIALS
      7.18.3 PRODUCTS & SERVICES
      7.18.4 STRATEGY
      7.18.5 DEVELOPMENTS
7.19 THEOREM CLINICAL RESEARCH
      7.19.1 OVERVIEW
      7.19.2 FINANCIALS
      7.19.3 PRODUCTS & SERVICES
      7.19.4 STRATEGY
      7.19.5 DEVELOPMENTS


LIST OFTABLES

TABLE 1 GLOBAL CLINICAL TRIALS, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 2 CLINICAL TRIALS APPROVAL: TIME & AUTHORITY
TABLE 3 DRUGS SET FOR PATENT EXPIRATIONS, 2010–2012
TABLE 4 PHASE I CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 5 GLOBAL PHASE I CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 6 PHASE II CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 7 GLOBAL PHASE II CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 8 PHASE I/II CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 9 GLOBAL PHASE I/II CLINICAL TRIALS, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 10 PHASE II/III CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 11 GLOBAL PHASE II/III CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 12 PHASE III CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 13 GLOBAL PHASE III CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 14 OBSERVATIONAL STUDIES: CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 15 INTERVENTIONAL STUDIES: CLINICAL TRIALS MARKET, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 16 EXPANDED ACCESS: CLINICAL TRIALS, BY GEOGRAPHY, 2007 – 2010 (NO. OF TRIALS)
TABLE 17 GLOBAL CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 18 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRIES, 2007 – 2010 (NO. OF TRIALS)
TABLE 19 U.S: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 20 U.S: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 21 U.S: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 22 CANCER FUNDING IN THE U.S., BY TYPES, 2008 – 2010 ($MILLION)
TABLE 23 CANADA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 24 CANADA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 25 CANADA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 26 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRIES, 2007 – 2010 (NO. OF TRIALS)
TABLE 27 UK: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 28 UK: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 29 UK: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 30 GERMANY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 31 GERMANY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 32 GERMANY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 33 ITALY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 34 ITALY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 35 ITALY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 36 FRANCE: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 37 FRANCE: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 38 FRANCE: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 39 SPAIN: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 40 SPAIN: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 41 SPAIN: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 42 POLAND: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 43 POLAND: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 44 POLAND: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 45 RUSSIA: CLINICAL TRIALS MARKET BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 46 RUSSIA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 47 RUSSIA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 48 TURKEY: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 49 TURKEY: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 50 TURKEY: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 51 UKRAINE: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 52 UKRAINE: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 53 UKRAINE: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 54 ASIA: CLINICAL TRIALS MARKET, BY COUNTRY, 2007 – 2010 (NO. OF TRIALS)
TABLE 55 CHINA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 56 CHINA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 57 CHINA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 58 INDIA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 59 INDIA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 60 INDIA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 61 SOUTH KOREA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 62 SOUTH KOREA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 63 SOUTH KOREA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 64 LATIN AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2007 – 2010 (NO. OF TRIALS)
TABLE 65 BRAZIL: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 66 BRAZIL: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 67 BRAZIL: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 68 MEXICO: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 69 MEXICO: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 70 MEXICO: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 71 ARGENTINA: CLINICAL TRIALS MARKET, BY PHASES, 2007 – 2010 (NO. OF TRIALS)
TABLE 72 ARGENTINA: CLINICAL TRIALS MARKET, BY STUDY DESIGNS, 2007 – 2010 (NO. OF TRIALS)
TABLE 73 ARGENTINA: CLINICAL TRIALS MARKET, BY INDICATIONS, 2007 – 2010 (NO. OF TRIALS)
TABLE 74 NEW APPROVALS, 2008 – 2010
TABLE 75 EXPANSIONS, 2008 – 2011
TABLE 76 NEW TRIALS, 2007 – 2011
TABLE 77 COLLABORATIONS & PARTNERSHIPS, 2008 – 2011
TABLE 78 MERGERS & ACQUISITIONS, 2007 – 2011
TABLE 79 CHILTERN: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 80 COVANCE INC: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 81 COVANCE INC.: TOTAL REVENUE, BY COUNTRY, 2008 – 2010 ($MILLION)
TABLE 82 COVANCE INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 83 ICON PLC: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 84 ICON PLC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 85 ICON PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 86 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 87 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 88 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 89 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, BY COUNTRY, 2008 – 2010 ($MILLION)
TABLE 90 PHARMACEUTICAL PRODUCT DEVELOPMENT INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 91 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, 2008 – 2010 ($MILLION)
TABLE 92 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, BY COUNTRY, 2008 – 2010 ($MILLION)
TABLE 93 THEOREM CLINICAL RESEARCH: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

LIST OFFIGURES

FIGURE 1 COUNTRY WISE PARAMETRIC COMPARISON
FIGURE 2 COST OF CLINICAL TRIALS, BY COUNTRY
FIGURE 3 U.S: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 4 CANADA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 5 UK: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 6 GERMANY: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 7 ITALY: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 8 FRANCE: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 9 SPAIN: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 10 POLAND: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 11 RUSSIA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 12 TURKEY: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 13 UKRAINE: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 14 CHINA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 15 INDIA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 16 SOUTH KOREA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 17 BRAZIL: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 18 MEXICO: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 19 ARGENTINA: CLINICAL TRIALS REGULATORY PROCESS
FIGURE 20 MAJOR GROWTH STRATEGIES IN GLOBAL CLINICAL TRIALS MARKET, JANUARY 2008 – JULY 2011

Global Clinical Trials Market to grow at a steady rate in Asia

The global clinical trials conducted in the year 2008 were reported to be 10,326 and were highest from 2007 to 2010.

Amongst all the market segments, the oncology trials market command the largest share according to indications. The oncology trials accounted for 28.47% of all the trials conducted for the year 2008.

Clinical trials market is increasing globally due to decrease in the naïve disease population in the developed countries, strict regulatory approvals and tight R&D budgets are forcing the sponsors to move to the east.

Asia offers a lucrative market to clinical trials market due to naïve population and nearly 50% low costs for conducting the trials as compared to the U.S. Although the greater timelines for approval is still a major concern for the sponsors Asia region reported to a steady growth as compared to the other regions that showed decline in the total number of clinical trials in the year 2010. Asia accounted the highest of 809 trials for the year 2010.

COMPETITIVE LANDSCAPE OF CLINICAL TRIALS MARKET

CROs with the most significant developments for clinical trials are – Chiltern, Quintles, PPD, and Omnicare. These CROs are undergoing various mergers and acquisitions for technology and to make a global presence with local CROs.

Custom Market Research Services